For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...
Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...
Pfizer Inc. pulled off a comeback win, beating out Danish drug giant Novo Nordisk to acquire obesity drug developer Metsera Inc. in a deal that values the biotechnology company at up to $9.1 billion.
Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...
Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...
Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...
Yao Pharma's deal with the US pharmaceutical giant underscores China's growing role in global biotech licensing US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback